Charlton R A, McGrogan A, Snowball J, Yates L M, Wood A, Clayton-Smith J, Smithson W H, Richardson J L, McHugh N, Thomas S H L, Baker G A, Bromley R
Department of Pharmacy and Pharmacology, University of Bath, Claverton Down, Bath, BA2 7AY, UK.
The UK Teratology Information Service, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
Drug Saf. 2017 May;40(5):387-397. doi: 10.1007/s40264-017-0506-5.
Electronic healthcare data have several advantages over prospective observational studies, but the sensitivity of data on neurodevelopmental outcomes and its comparability with data generated through other methodologies is unknown.
The objectives of this study were to determine whether data from the UK Clinical Practice Research Datalink (CPRD) produces similar risk estimates to a prospective cohort study in relation to the risk of neurodevelopmental disorders (NDDs) following prenatal antiepileptic drug (AED) exposure.
A cohort of mother-child pairs of women with epilepsy (WWE) was identified in the CPRD and matched to a cohort without epilepsy. The study period ran from 1 January 2000 to 31 March 2007 and children were required to be in the CPRD at age 6 years. AED exposure during pregnancy was determined from prescription data and children with an NDD diagnosis by 6 years were identified from Read clinical codes. The prevalence and risk of NDDs was calculated for mother-child pairs in WWE stratified by AED regimen and for those without epilepsy. Comparisons were made with the results of the prospective Liverpool and Manchester Neurodevelopment Group study which completed assessment on 201 WWE and 214 without epilepsy at age 6 years.
In the CPRD, 1018 mother-child pairs to WWE and 6048 to women without epilepsy were identified. The CPRD identified a lower prevalence of NDDs than the prospective study. In both studies, NDDs were more frequently reported in children of WWE than women without epilepsy, although the CPRD risk estimate was lower (2.16 vs. 0.96%, p < 0.001 and 7.46 vs. 1.87%, p = 0.0128). NDD prevalence differed across AED regimens but the CPRD data did not replicate the significantly higher risk of NDDs following in utero monotherapy valproate exposure (adjusted odds ratio [OR] 2.02, 95% confidence interval [CI] 0.52-7.86) observed in the prospective study (OR 6.05, 95% CI 1.65-24.53).
It was possible to identify NDDs in the CPRD; however, the CPRD appears to under-record these outcomes. Larger studies are required to investigate further.
电子医疗数据相较于前瞻性观察性研究具有若干优势,但神经发育结局数据的敏感性及其与通过其他方法生成的数据的可比性尚不清楚。
本研究的目的是确定来自英国临床实践研究数据链(CPRD)的数据在产前接触抗癫痫药物(AED)后神经发育障碍(NDD)风险方面是否能产生与前瞻性队列研究相似的风险估计。
在CPRD中识别出一组患有癫痫的母婴对(WWE),并与一组无癫痫的队列进行匹配。研究期间为2000年1月1日至2007年3月31日,要求儿童在6岁时纳入CPRD。根据处方数据确定孕期AED暴露情况,并通过Read临床编码识别6岁时诊断为NDD的儿童。计算WWE中按AED治疗方案分层的母婴对以及无癫痫者中NDD的患病率和风险。与前瞻性利物浦和曼彻斯特神经发育组研究的结果进行比较,该研究在6岁时对201名WWE和214名无癫痫者完成了评估。
在CPRD中,识别出1018对WWE母婴对和6048对无癫痫女性母婴对。CPRD识别出的NDD患病率低于前瞻性研究。在两项研究中,WWE儿童中报告的NDD均比无癫痫女性更频繁,尽管CPRD的风险估计较低(2.16%对0.96%,p<0.001;7.46%对1.87%,p = 0.0128)。不同AED治疗方案的NDD患病率不同,但CPRD数据未重现前瞻性研究中观察到的宫内丙戊酸单药治疗后NDD风险显著更高的情况(调整比值比[OR] 2.02,95%置信区间[CI] 0.52 - 7.86)(OR 6.05,95% CI 1.65 - 24.53)。
在CPRD中能够识别出NDD;然而,CPRD似乎对这些结局记录不足。需要开展更大规模的研究进行进一步调查。